Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid

Trump Declares Opioids a U.S. Public Health Emergency

Yasmeen Abutaleb and Jeff Mason  |  October 27, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump declared the opioid crisis a public health emergency on Thursday, stopping short of a national emergency declaration he promised months ago that would have freed up more federal money. Responding to a growing problem wreaking havoc in rural areas, Trump’s declaration will redirect federal resources and loosen regulations to combat…

Filed under:Drug Updates Tagged with:Fentanylnational opioid addiction epidemicopioid crisisprescription painkillersU.S. public health emergency

FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2017

The FDA is expanding its Risk Evaluation and Mitigation Strategy (REMS) to include manufacturers of immediate-release opioids. The makers of these drugs will soon be required to provide training and education to healthcare professionals on the proper prescription and use of the drugs for pain management…

Filed under:AnalgesicsDrug Updates Tagged with:FDAopioidOpioid abuseREMSU.S. Food and Drug Administration (FDA)

U.S. to Promote Use of Opioid Alternatives to Treat Addiction

Toni Clarke  |  October 26, 2017

(Reuters)—The U.S. Food and Drug Administration plans to encourage opioid addicts to use less harmful opioid drugs such as methadone and buprenorphine, a radical shift in policy that could agitate those in the addiction field who believe abstinence is the only effective treatment. Speaking before the House Committee on Energy and Commerce on Wednesday, FDA…

Filed under:Drug Updates Tagged with:addiction treatmentbuprenorphineFDA Commissioner Scott Gottliebmethadonenational opioid addiction epidemicopioid alternativesopioid crisisopioid substituteU.S. Food and Drug Administration (FDA)

Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme

Nate Raymond  |  October 26, 2017

BOSTON (Reuters)—A Rhode Island doctor pleaded guilty on Wednesday to charges he participated in a scheme to obtain kickbacks in exchange for writing prescriptions for an addictive fentanyl-based cancer pain drug produced by Insys Therapeutics Inc. The plea by Jerrold Rosenberg came amid ongoing investigations of Insys related to Subsys, an under-the-tongue spray that contains…

Filed under:EthicsLegal Updates Tagged with:Cancerfentanyl-based cancer pain drugguilty pleahealthcare fraudInsys Therapeutics IncJerrold Rosenbergnational opioid addiction epidemicopioid crisisopioid kickback schemeRhode Island doctor

New Jersey Sues Insys as Opioid Maker Settles with Massachusetts

Nate Raymond  |  October 5, 2017

BOSTON (Reuters)—New Jersey on Thursday accused Insys Therapeutics Inc of engaging in a fraudulent scheme to boost sales of a fentanyl-based cancer pain drug, as Massachusetts announced a $500,000 settlement with the drugmaker to resolve similar allegations. The lawsuit by New Jersey Attorney General Christopher Porrino accused Insys of illegally directing its sales force to…

Filed under:Drug UpdatesLegal Updates Tagged with:Cancerfentanyl-based cancer pain drugInsys Therapeutics IncNew Jersey Attorney General Christopher PorrinoNew Jersey lawsuitopioid crisis

Makers of Fast-Acting Opioids Will Have to Pay for Training—FDA

Michael Erman  |  September 29, 2017

NEW YORK (Reuters)—Makers of fast-acting opioids will have to fund voluntary training for healthcare professionals who prescribe the drugs, including education on safe prescribing practices and non-opioid alternatives, the course  said on Thursday. The FDA sent letters to 74 manufacturers of immediate-release opioids, notifying them that they will have to fund the development of courses…

Filed under:Drug UpdatesEducation & Training Tagged with:course fundingfast-acting opioidsopioid drug companiesU.S. Food and Drug Administration (FDA)

Unbudgeted: How the Opioid Crisis Is Blowing a Hole in Small-Town America’s Finances

Paula Seligson & Tim Reid  |  September 20, 2017

INDIANA, Pa./CHILLICOTHE, Ohio (Reuters)—As deaths mount in America’s opioid crisis, communities on the front lines face a hidden toll: the financial cost. Ross County, a largely rural region of 77,000 people an hour south of Columbus, Ohio, is wrestling with an explosion in opioid-related deaths—44 last year compared with 19 in 2009. The drug addiction…

Filed under:AnalgesicsDrug Updates

Prosecutors Identify Insys Founder as Unindicted Co-conspirator in Opioid Case

Nate Raymond  |  September 14, 2017

BOSTON (Reuters)—U.S. prosecutors have identified Insys Therapeutics Inc’s billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document. John Kapoor, who stepped down as chief executive of Insys in January, was…

Filed under:Legal Updates Tagged with:Insys Therapeutics IncJohn Kapooropioid crisisopioid drug companiesOpioid drugmaker probe

U.S. Senator Reveals Results of Opioid Inquiry into Insys

Nate Raymond  |  September 7, 2017

BOSTON (Reuters)—Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report, released by Democratic Senator Claire McCaskill, said those efforts led to an Insys employee making misleading statements…

Filed under:Drug UpdatesLegal Updates Tagged with:Insys Therapeutics Incopioid crisisSubsys opioid drugU.S. Democratic Senator Claire McCaskillU.S. Senate report

Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme

Nate Raymond  |  August 31, 2017

(Reuters)—Arizona’s attorney general sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine. The lawsuit by Arizona Attorney General Mark Brnovich in Maricopa County Superior Court in Phoenix comes during a series of federal and state investigations centered on…

Filed under:Drug UpdatesLegal Updates Tagged with:Arizona Attorney General Mark Brnovichfraudulent marketing schemeInsys Therapeutics Inclawsuitopioid crisisSubsys opioid drug

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences